Rowan Saloner1, Mariana Cherner2, David J Grelotti2, Emily W Paolillo3, David J Moore2, Robert K Heaton2, Scott L Letendre2, Adarsh Kumar4, Igor Grant2, Ronald J Ellis5. 1. San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA; Department of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA. Electronic address: rsaloner@ucsd.edu. 2. Department of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA. 3. San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA; Department of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA. 4. Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, USA. 5. Department of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA; Department of Neurosciences, University of California, San Diego, San Diego, CA, USA.
Abstract
BACKGROUND: HIV-related neuroinflammation has been proposed as a catalyst for dopaminergic dysregulation in mesocortical pathways, which may contribute to the pathogenesis of depression. Abnormalities in dopaminergic neurotransmission and depression are common in people with HIV (PWH), however the link between dopamine (DA) and depression in PWH is poorly characterized. This study investigated CSF dopaminergic biomarkers, specifically DA and its metabolite, homovanillic acid (HVA), and examined their relationship with depressive symptoms and CSF neuroinflammatory markers in PWH and HIV-seronegative (HIV-) individuals. METHODS: Participants were 102 HIV- individuals and 123 PWH (mean age = 42) who underwent neuropsychiatric evaluations and lumbar puncture. Current depression severity was classified using the Beck Depression Inventory-II (BDI-II). CSF was assayed for DA and HVA using high performance liquid chromatography and neuroinflammatory markers using immunoassays. Linear regressions modelled BDI-II scores as a function of HIV, dopaminergic biomarker z-scores, and their interaction, controlling for psychosocial factors. Correlational analyses examined dopaminergic and neuroinflammatory relationships. RESULTS: PWH had significantly higher BDI-II scores than HIV- participants. DA and HVA were not associated with HIV status but both significantly moderated the effect of HIV on BDI-II scores, such that PWH exhibited higher depressive symptoms than HIV- participants only at lower concentrations of HVA (z ≤ 0.06) and DA (z ≤ 0.11). In PWH only, lower HVA significantly correlated with higher BDI-II scores and higher neuroinflammation, including higher MCP-1 and IP-10. CONCLUSIONS: Results suggest that the pathophysiology of depression in PWH differs from that in HIV- individuals. Specifically, lower central dopaminergic activity was selectively associated with greater depressive symptoms and neuroinflammation in PWH. With the rise in consideration of DA agonists for the treatment of depression, these results suggest that PWH may show a greater response to these agents than their HIV- peers.
BACKGROUND: HIV-related neuroinflammation has been proposed as a catalyst for dopaminergic dysregulation in mesocortical pathways, which may contribute to the pathogenesis of depression. Abnormalities in dopaminergic neurotransmission and depression are common in people with HIV (PWH), however the link between dopamine (DA) and depression in PWH is poorly characterized. This study investigated CSF dopaminergic biomarkers, specifically DA and its metabolite, homovanillic acid (HVA), and examined their relationship with depressive symptoms and CSF neuroinflammatory markers in PWH and HIV-seronegative (HIV-) individuals. METHODS:Participants were 102 HIV- individuals and 123 PWH (mean age = 42) who underwent neuropsychiatric evaluations and lumbar puncture. Current depression severity was classified using the Beck Depression Inventory-II (BDI-II). CSF was assayed for DA and HVA using high performance liquid chromatography and neuroinflammatory markers using immunoassays. Linear regressions modelled BDI-II scores as a function of HIV, dopaminergic biomarker z-scores, and their interaction, controlling for psychosocial factors. Correlational analyses examined dopaminergic and neuroinflammatory relationships. RESULTS:PWH had significantly higher BDI-II scores than HIV- participants. DA and HVA were not associated with HIV status but both significantly moderated the effect of HIV on BDI-II scores, such that PWH exhibited higher depressive symptoms than HIV- participants only at lower concentrations of HVA (z ≤ 0.06) and DA (z ≤ 0.11). In PWH only, lower HVA significantly correlated with higher BDI-II scores and higher neuroinflammation, including higher MCP-1 and IP-10. CONCLUSIONS: Results suggest that the pathophysiology of depression in PWH differs from that in HIV- individuals. Specifically, lower central dopaminergic activity was selectively associated with greater depressive symptoms and neuroinflammation in PWH. With the rise in consideration of DA agonists for the treatment of depression, these results suggest that PWH may show a greater response to these agents than their HIV- peers.
Authors: Paolo Barone; Werner Poewe; Stefan Albrecht; Catherine Debieuvre; Dan Massey; Olivier Rascol; Eduardo Tolosa; Daniel Weintraub Journal: Lancet Neurol Date: 2010-05-07 Impact factor: 44.182
Authors: Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2004-05 Impact factor: 2.475
Authors: Jennifer C Felger; Li Li; Paul J Marvar; Bobbi J Woolwine; David G Harrison; Charles L Raison; Andrew H Miller Journal: Brain Behav Immun Date: 2012-10-13 Impact factor: 7.217
Authors: Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2016-08-02 Impact factor: 4.147
Authors: Chad A Bousman; Mariana Cherner; Stephen J Glatt; J Hampton Atkinson; Igor Grant; Ming T Tsuang; Ian P Everall Journal: Neurobehav HIV Med Date: 2010-01-01
Authors: K Blackstone; D J Moore; D R Franklin; D B Clifford; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; R J Ellis; J H Atkinson; I Grant; R K Heaton Journal: Clin Neuropsychol Date: 2012-06-18 Impact factor: 3.535
Authors: Albert M Anderson; Christine Fennema-Notestine; Anya Umlauf; Michael J Taylor; David B Clifford; Christina M Marra; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; David M Simpson; Susan Morgello; Igor Grant; Scott L Letendre Journal: J Neurovirol Date: 2015-06-12 Impact factor: 3.739
Authors: Magnus Gisslen; Sheila M Keating; Serena Spudich; Victor Arechiga; Sophie Stephenson; Henrik Zetterberg; Clara Di Germanio; Kaj Blennow; Dietmar Fuchs; Lars Hagberg; Philip J Norris; Julia Peterson; Barbara L Shacklett; Constantin T Yiannoutsos; Richard W Price Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240
Authors: Rowan Saloner; Erin E Morgan; Mariam A Hussain; David J Moore; Robert K Heaton; Mariana Cherner; Igor Grant; Jennifer E Iudicello Journal: J Neurovirol Date: 2022-01-03 Impact factor: 3.739
Authors: K M Emanuel; K Runner; Z D Brodnik; B M Morsey; B G Lamberty; H S Johnson; A Acharya; S N Byrareddy; R A España; H S Fox; P J Gaskill Journal: iScience Date: 2022-04-06
Authors: Rowan Saloner; Emily W Paolillo; Robert K Heaton; David J Grelotti; Murray B Stein; Andrew H Miller; J Hampton Atkinson; Scott L Letendre; Ronald J Ellis; Igor Grant; Jennifer E Iudicello; David J Moore Journal: J Neurovirol Date: 2021-01-06 Impact factor: 3.739